Does BOLD pay a dividend?

The cached stock data on this page does not show a positive dividend yield for BOLD. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does BOLD stock do?

Clinical-stage oncology biopharmaceutical company developing therapies targeting extrachromosomal DNA (ecDNA) in oncogene-amplified cancers. Currently pre-revenue with zero commercial sales.

What is BOLD stock's price target?

This cached page does not contain a precise model fair value for BOLD.

The TradeMates model verdict for BOLD is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.

Is BOLD a good dividend stock?

BOLD is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

BOLD (BOLD) Stock Analysis

Q: Is BOLD stock a good investment?

The cached TradeMates AI model rates BOLD as AVOID with an investment score of 31/100. The model views Boundless Bio as a high-risk microcap biotech. Impending capital dilution and zero revenue outweigh speculative ecDNA clinical upside and insider accumulation. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

Pre-revenue ecDNA oncology pipeline faces acute dilution risk with under 5 months cash runway despite insider buying.

Investment score: 31/100

The model views Boundless Bio as a high-risk microcap biotech. Impending capital dilution and zero revenue outweigh speculative ecDNA clinical upside and insider accumulation.

View the full interactive analysis